MannKind
MannKind Corporation is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on orphan lung and cardiometabolic diseases, we develop and commercialize treatments that address serious unmet medical needs, including idiopathic pulmonary fibrosis, pulmonary hypertension, diabetes, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
